- Home
- CELU vs VTVT Comparison
CELU vs VTVT Comparison
Compare CELU & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- VTVT
- Stock Information
- Founded
- CELU 2016
- VTVT 2015
- Country
- CELU United States
- VTVT United States
- Employees
- CELU N/A
- VTVT N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- CELU Health Care
- VTVT Health Care
- Exchange
- CELU Nasdaq
- VTVT Nasdaq
- Market Cap
- CELU 56.9M
- VTVT 54.4M
- IPO Year
- CELU N/A
- VTVT 2015
- Fundamental
- Price
- CELU $1.74
- VTVT $23.99
- Analyst Decision
- CELU Strong Buy
- VTVT Strong Buy
- Analyst Count
- CELU 1
- VTVT 2
- Target Price
- CELU $6.00
- VTVT $35.50
- AVG Volume (30 Days)
- CELU 153.9K
- VTVT 4.8K
- Earning Date
- CELU 12-05-2025
- VTVT 11-12-2025
- Dividend Yield
- CELU N/A
- VTVT N/A
- EPS Growth
- CELU N/A
- VTVT N/A
- EPS
- CELU N/A
- VTVT N/A
- Revenue
- CELU $44,590,000.00
- VTVT $17,000.00
- Revenue This Year
- CELU N/A
- VTVT N/A
- Revenue Next Year
- CELU $76.00
- VTVT N/A
- P/E Ratio
- CELU N/A
- VTVT N/A
- Revenue Growth
- CELU 4.45
- VTVT N/A
- 52 Week Low
- CELU $1.00
- VTVT $12.62
- 52 Week High
- CELU $5.22
- VTVT $26.99
- Technical
- Relative Strength Index (RSI)
- CELU 34.57
- VTVT 66.89
- Support Level
- CELU $1.62
- VTVT $19.80
- Resistance Level
- CELU $1.99
- VTVT $25.30
- Average True Range (ATR)
- CELU 0.11
- VTVT 1.25
- MACD
- CELU -0.02
- VTVT 0.18
- Stochastic Oscillator
- CELU 21.15
- VTVT 76.18
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.